Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Arrowhead Pharmaceuticals, Inc. before investing.

In this article, we go over a few key elements for understanding Arrowhead Pharmaceuticals, Inc.’s stock price such as:

• Arrowhead Pharmaceuticals, Inc.’s current stock price and volume
• Why Arrowhead Pharmaceuticals, Inc.’s stock price changed recently
• Upgrades and downgrades for ARWR from analysts
• ARWR’s stock price momentum as measured by its relative strength

About Arrowhead Pharmaceuticals, Inc. (ARWR)

Before we jump into Arrowhead Pharmaceuticals, Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California.

Want to learn more about Arrowhead Pharmaceuticals, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Arrowhead Pharmaceuticals, Inc..

Arrowhead Pharmaceuticals, Inc.’s Stock Price as of Market Close

As of November 26, 2025, 4:00 PM, CST, Arrowhead Pharmaceuticals, Inc.’s stock price was $57.710.

Arrowhead Pharmaceuticals, Inc. is up 23.34% from its previous closing price of $46.790.

During the last market session, Arrowhead Pharmaceuticals, Inc.’s stock traded between $45.090 and $59.150. Currently, there are approximately 137.88 million shares outstanding for Arrowhead Pharmaceuticals, Inc..

Arrowhead Pharmaceuticals, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Arrowhead Pharmaceuticals, Inc. Stock Price History

Arrowhead Pharmaceuticals, Inc.’s (ARWR) price is currently up 36.14% so far this month.

During the month of November, Arrowhead Pharmaceuticals, Inc.’s stock price has reached a high of $59.150 and a low of $37.060.

Over the last year, Arrowhead Pharmaceuticals, Inc. has hit prices as high as $59.150 and as low as $9.570. Year to date, Arrowhead Pharmaceuticals, Inc.’s stock is up 206.97%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Arrowhead Pharmaceuticals, Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of November 26, 2025, there was 1 analyst who downgraded Arrowhead Pharmaceuticals, Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Arrowhead Pharmaceuticals, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Arrowhead Pharmaceuticals, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Arrowhead Pharmaceuticals, Inc.’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Arrowhead Pharmaceuticals, Inc. (ARWR) by visiting AAII Stock Evaluator.

Relative Price Strength of Arrowhead Pharmaceuticals, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of November 26, 2025, Arrowhead Pharmaceuticals, Inc. has a weighted four-quarter relative price strength of 61.87%, which translates to a Momentum Score of 98 and is considered to be Very Strong.

Want to learn more about how Arrowhead Pharmaceuticals, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Arrowhead Pharmaceuticals, Inc. Stock Price: Bottom Line

As of November 26, 2025, Arrowhead Pharmaceuticals, Inc.’s stock price is $57.710, which is up 23.34% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Arrowhead Pharmaceuticals, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.